Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
From Jan 2022: how each company's value moved, whatever its size.
US$ billions, as reported in each year's annual results.
Revenue of the fiscal year. US dollars at each year's exchange rate.
| Measure | Celularity Inc.✕ CELU · #23,307 in the world | NextCure, Inc.✕ NXTC · #23,078 in the world |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Founded | — | — |
| Size | ||
| Market cap | ||
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | Celularity Inc. | NextCure, Inc. |
|---|---|---|
| 2025 | $27 MSEC | — |
| 2024 | $54 MSEC | — |
| 2023 | $23 MSEC | — |
| 2022 | $18 MSEC | — |
| 2021 | $21 MSEC | — |
| 2020 | $14 MSEC | $22 MSEC |
| 2019 | — | $6 MSEC |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| $28 M |
| $30 M |
| Revenue | $27 M | — |
|---|
| Net income | $-92 M | $-56 M▲ best |
|---|
| Employees | 288 | — |
|---|
| Valuation | ||
|---|---|---|
| Price to sales | 1.5× | — |
| Price to book | — | 0.9× |
| Free cash flow yield | -23.8%▲ best | -138.0% |
| Profitability | ||
|---|---|---|
| Gross margin | 24.4% | — |
| Operating margin | -230.9% | — |
| Net margin | -345.5% | — |
| Return on equity | — | -111.2% |
| Growth | ||
|---|---|---|
| Revenue growth | -51.0% | — |
| Revenue growth, 3 years a year | 13.9% | — |
| Altman Z-score zone | distress | — |
|---|
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap Oct 2026; ratios FY2025 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.